BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement
Advertisement

Free Content

Use our marquee links to make BioCentury This Week part of your home page! Our player style marquee links below make it very easy to do.

Your Webmaster can follow these easy steps:

  1. Select the program from the list below to which you want to link.
  2. Copy the html code in the box for that segment.
  3. Paste the copied html code into your home page.

If you want to link to multiple segments, select the first of your choices as the marquee link. The segments that follow will play automatically after your selection.

Questions: jfitzgerald@biocentury.com

That's it! You now have a marquee link like the one above.

NOTICE:
BioCentury Publications, Inc., and WUSA-TV own the copyright to the program content on "BioCentury This Week," and except for limited use of these links to the BioCenturytv.com website, BioCentury and WUSA prohibit hosting of BioCentury This Week program content by unauthorized third parties or posting of BioCentury This Week content to any unauthorized third party websites such as YouTube. Other BioCenturytv.com content and all trademarks are the property of BioCentury or WUSA-TV or other third parties.

Questions on authorized use may be directed to jfitzgerald@biocentury.com

 
BioCentury 07.27.14 - [1] Chargeback
BioCentury 07.27.14 - [1] Chargeback
Berkeley Research Group's Aaron Vandervelde discusses research which may explain the possible relationship between hospital acquisitions of community oncology practices and the revenue-generating 340-B program.
COPY THIS CODE:
 
 
BioCentury 07.27.14 - [2] Billions of Dollars
BioCentury 07.27.14 - [2] Billions of Dollars
Managing Director of Reimbursement and Health Policy of the Biotechnology Industry Organization, Laurel Todd, says oversight of the 340-B program has not kept pace with its rapid growth in the past 20 years.
COPY THIS CODE:
 
 
BioCentury 07.27.14 - [3] Transparency
BioCentury 07.27.14 - [3] Transparency
Todd says that pharmaceutical companies - which provide drug discounts under the 340-B program - want more oversight to ensure that safety net hospitals use revenues as intended: to offset costs of charity care.
COPY THIS CODE:
 
 
BioCentury 07.27.14 - [4] Profiles: Gene Editing
BioCentury 07.27.14 - [4] Profiles: Gene Editing
UC Berkeley researcher, Dr. Jennifer Doudna, explains CRISPR: repeated nucleotide patterns showing adaptive immune responses of bacteria to phages; the discovery allows for precise changes to genetic code.
COPY THIS CODE:
 
User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement